Respiratory Disorders
Interstitial lung disease (ILD) is recognized as one of the most frequent and potentially life-threatening pulmonary complications of systemic autoimmune rheumatic diseases (SARDs), a group of rare chronic inflammatory conditions characterized by autoimmune system dysregulation and chronic systemic inflammation. ILDs ...
As touchIMMUNOLOGY approaches 20 years of providing education for busy immunologists, we are looking to the future—and it certainly looks bright!
Interstitial lung disease (ILD) is a common and potentially fatal complication of systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD may be the first sign of disease or develop later, often with variable clinical courses. Early detection is critical, as delayed diagnosis contributes to poor outcomes. In response, the 2023 American College of Rheumatology (ACR) guidelines emphasize routine screening and risk-based strategies to improve identification and management of SARD-associated ILD (SARD-ILD).
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
It was a pleasure to meet with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) to explore the efficacy and safety findings from the phase 3 study of MV130 for the prevention of COPD exacerbations. The abstract 'Randomized, ...
It was great to talk with Dr Luis Puente-Maestu (Hospital General Universitario Gregorio Marañón, Madrid, Spain) around the abstract 'Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations.' (Presentation ID 207), ...
We spoke with Elliot Israel (Harvard Medical School, Boston, MA, USA) about the advances being made with biologics in the treatment of type 2 asthma. Questions How have biologic therapies transformed the management of severe asthma? (0:25) What have recent clinical trial ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
